PURPOSE: Cancer survivors commonly experience fatigue, related to disease and its treatment. This study aimed to compare fatigue severity among survivors of different cancer types with a normative population and also to identify variations in fatigue among cancer survivors according to clinical and demographic variables. METHODS: We used cancer survivorship data from the population-based PROFILES registry. We included survivors of endometrial (EC, n = 741) or colorectal cancer (CRC, n = 3878) (1998-2007), thyroid cancer (TC, n = 306) (1990-2008), Hodgkin (HL, n = 150) or non-Hodgkin lymphoma (NHL, n = 716), or multiple myeloma (MM, n = 120) (1999-2008). A representative Dutch normative population (n = 2040) was also assessed. Participants completed the Fatigue Assessment Scale. RESULTS: Cancer survivors were more often classified as fatigued (EC/CRC 39%, HL 40%, NHL 43%, MM 51%, TC 44%) compared with the normative population (21 %; p < 0.001). MM survivors were more often classified as fatigued than all other cancer groups, except NHL (overall p = 0.02). Shorter times since diagnosis (<5 years, 41 versus 38%; p < 0.05), younger age (≤65 years, 42 versus 39%; p < 0.01), being female (43 versus 36%; p < 0.01), chemotherapy treatment (43 versus 39%; p < 0.01), comorbidity (no (27%) versus 1 (35%) versus ≥2 (52%); p < 0.01), educational level (low (44%) versus medium (41%) versus high (32%); p < 0.01), and absence of a partner (47 versus 38%; p < 0.01) were associated with fatigue. CONCLUSIONS: Fatigue levels are substantial in (long-term) cancer survivors and vary depending on cancer type, time since diagnosis, age, gender, treatment with chemotherapy, number of comorbid conditions, educational level, and partnership. Since significantly more cancer survivors feel fatigued in comparison with the normative population, appropriate information, assessment, and interventions for fatigue are needed during or after oncologic treatment. Furthermore, focus on better control or management of comorbid conditions of cancer survivors is recommended.
PURPOSE:Cancer survivors commonly experience fatigue, related to disease and its treatment. This study aimed to compare fatigue severity among survivors of different cancer types with a normative population and also to identify variations in fatigue among cancer survivors according to clinical and demographic variables. METHODS: We used cancer survivorship data from the population-based PROFILES registry. We included survivors of endometrial (EC, n = 741) or colorectal cancer (CRC, n = 3878) (1998-2007), thyroid cancer (TC, n = 306) (1990-2008), Hodgkin (HL, n = 150) or non-Hodgkin lymphoma (NHL, n = 716), or multiple myeloma (MM, n = 120) (1999-2008). A representative Dutch normative population (n = 2040) was also assessed. Participants completed the Fatigue Assessment Scale. RESULTS:Cancer survivors were more often classified as fatigued (EC/CRC 39%, HL 40%, NHL 43%, MM 51%, TC 44%) compared with the normative population (21 %; p < 0.001). MM survivors were more often classified as fatigued than all other cancer groups, except NHL (overall p = 0.02). Shorter times since diagnosis (<5 years, 41 versus 38%; p < 0.05), younger age (≤65 years, 42 versus 39%; p < 0.01), being female (43 versus 36%; p < 0.01), chemotherapy treatment (43 versus 39%; p < 0.01), comorbidity (no (27%) versus 1 (35%) versus ≥2 (52%); p < 0.01), educational level (low (44%) versus medium (41%) versus high (32%); p < 0.01), and absence of a partner (47 versus 38%; p < 0.01) were associated with fatigue. CONCLUSIONS:Fatigue levels are substantial in (long-term) cancer survivors and vary depending on cancer type, time since diagnosis, age, gender, treatment with chemotherapy, number of comorbid conditions, educational level, and partnership. Since significantly more cancer survivors feel fatigued in comparison with the normative population, appropriate information, assessment, and interventions for fatigue are needed during or after oncologic treatment. Furthermore, focus on better control or management of comorbid conditions of cancer survivors is recommended.
Authors: Floortje Mols; Melissa S Y Thong; Lonneke V van de Poll-Franse; Jan Anne Roukema; Johan Denollet Journal: J Affect Disord Date: 2011-09-23 Impact factor: 4.839
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941
Authors: Meaghan L Khan; Craig B Reeder; Shaji K Kumar; Marthy Q Lacy; Donna E Reece; Angela Dispenzieri; Morie A Gertz; Phillip Greipp; Suzanne Hayman; Steven Zeldenhurst; David Dingli; John Lust; Stephen Russell; Kristina M Laumann; Joseph R Mikhael; P Leif Bergsagel; Rafael Fonseca; S Vincent Rajkumar; A Keith Stewart Journal: Br J Haematol Date: 2011-11-23 Impact factor: 6.998
Authors: Martine M Goedendorp; Michael A Andrykowski; Kristine A Donovan; Heather S Jim; Kristin M Phillips; Brent J Small; Christine Laronga; Paul B Jacobsen Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: Melissa S Y Thong; Floortje Mols; Xin S Wang; Valery E P P Lemmens; Tineke J Smilde; Lonneke V van de Poll-Franse Journal: Eur J Cancer Date: 2013-03-01 Impact factor: 9.162
Authors: Olga Husson; Willy-Anne Nieuwlaat; Wilma A Oranje; Harm R Haak; Lonneke V van de Poll-Franse; Floortje Mols Journal: Thyroid Date: 2013-07-25 Impact factor: 6.568
Authors: Floortje Mols; Johan Denollet; Adrian A Kaptein; Peter H M Reemst; Melissa S Y Thong Journal: J Psychosom Res Date: 2012-07-24 Impact factor: 3.006
Authors: Kristin Valborg Reinertsen; Milada Cvancarova; Jon H Loge; Hege Edvardsen; Erik Wist; Sophie D Fosså Journal: J Cancer Surviv Date: 2010-09-23 Impact factor: 4.442
Authors: Li Rebekah Feng; Brian S Wolff; Nada Lukkahatai; Alexandra Espina; Leorey N Saligan Journal: Cancer Nurs Date: 2017 May/Jun Impact factor: 2.592
Authors: Hiroko Kunitake; Marcia M Russell; Ping Zheng; Greg Yothers; Stephanie R Land; Laura Petersen; Louis Fehrenbacher; Jeffery K Giguere; D Lawrence Wickerham; Clifford Y Ko; Patricia A Ganz Journal: J Cancer Surviv Date: 2016-08-25 Impact factor: 4.442
Authors: Ellen Krueger; Ekin Secinti; Catherine E Mosher; Patrick V Stutz; Andrea A Cohee; Shelley A Johns Journal: Cancer Nurs Date: 2021 Nov-Dec 01 Impact factor: 2.592
Authors: Janna L Koole; Martijn J L Bours; Anne J M R Geijsen; Biljana Gigic; Arve Ulvik; Dieuwertje E Kok; Stefanie Brezina; Jennifer Ose; Andreas Baierl; Jürgen Böhm; Hermann Brenner; Stéphanie O Breukink; Jenny Chang-Claude; Fränzel J B van Duijnhoven; Peter van Duijvendijk; Tanja Gumpenberger; Nina Habermann; Henk K van Halteren; Michael Hoffmeister; Andreana N Holowatyj; Maryska L G Janssen-Heijnen; Eric T P Keulen; Rama Kiblawi; Flip M Kruyt; Christopher I Li; Tengda Lin; Øivind Midttun; Anita R Peoples; Eline H van Roekel; Martin A Schneider; Petra Schrotz-King; Alexis B Ulrich; Kathy Vickers; Evertine Wesselink; Johannes H W de Wilt; Andrea Gsur; Per M Ueland; Cornelia M Ulrich; Ellen Kampman; Matty P Weijenberg Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045
Authors: Nadine Linendoll; Tully Saunders; Rebecca Burns; Jonathan D Nyce; Kristen B Wendell; Andrew M Evens; Susan K Parsons Journal: Health Qual Life Outcomes Date: 2016-07-29 Impact factor: 3.186